March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Suramin and PPADS Downregulate Proinflammatory Citokines in the Retina of a Rat Model of Type 1 Diabetes
Author Affiliations & Notes
  • Juan E. Gallo
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
    Nanomedicine & Vision Group, Universidad Austral, Pilar, Argentina
  • Jorge E. Mancini
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
  • Juan O. Croxatto
    Eye Pathology, Fundacion Oftalmol Argentina J Malbran, Ciudad de Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships  Juan E. Gallo, None; Jorge E. Mancini, None; Juan O. Croxatto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3285. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juan E. Gallo, Jorge E. Mancini, Juan O. Croxatto; Suramin and PPADS Downregulate Proinflammatory Citokines in the Retina of a Rat Model of Type 1 Diabetes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3285.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the expression of TNF-a, IL-17, c-PLA2, GFAP and P2X2 in the retina of type 1 diabetic rat treated with PPADS and Suramin

Methods: : Sixteen male Wistar rats of 250gr were treated with an intraperitoneal injection of 45mg/kg of streptozotocin. Only animals with glycemia levels above 200mg/dl were included in the study. The treated animals were divided into three groups of 4 rats. These were intraperitoneally injected with: 1) Suramin, 2) PPADS, 3) Suramin + PPADS at 9 and 26 weeks of diabetes in each group. Four remaining diabetic animals received no treatment. Twelve non-diabetic rats with the same age of diabetics were used as a control group. Animals were sacrificed after 38 weeks of diabetes. Cross sections of retinas were analyzed by immunohistochemistry using primary antibodies against GFAP, TNF-alfa, IL-17, cPLA2 and P2X2 receptor.

Results: : Immunostaining of the analyzed antibodies were clearly up-regulated in diabetic animals without treatment. Diabetic rats treated with Suramin, PPADS and the combined compound showed up a pattern and immunostaining similar to that seen in the control group. Staining was much lower in animals treated with suramin than that found in those treated with PPADS

Conclusions: : Suramin and PPADS may be good therapeutical candidates for the treatment of diabetic retinopathy during the inflammatory stage of the disease. Further studies are being conducted.

Keywords: diabetic retinopathy • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.